Drugs / NL201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04659629 | Apr 2021 → Dec 2022 | neoplasm | Neurogene Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01663441 Comparator | Mar 2015 → Aug 2017 | thrombocytopenia | Beijing Northland Biotech. Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NL-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04659629 ↗ |
| Modality | Protein / enzyme biologic | “NL-201 is a de novo protein therapeutic.” NCT04659629 ↗ |
| Route | Intravenous | “NL-201 when given intravenously as monotherapy” NCT04659629 ↗ |